TEL AVIV, Israel, May 17, 2022 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic, fibrosis and ...
Sapu Bioscience LLC announced the expansion of its Phase 1b clinical development program for Sapu003 (Everolimus for ...
More flexibility in early-phase development for cell therapies is needed, a panel of US Food and Drug Administration (FDA) ...
OXFORD, England--(BUSINESS WIRE)--Exscientia plc (Nasdaq: EXAI) today announced the appointment of two technology and clinical development leaders to senior roles to significantly strengthen the ...
Discusses Clinical Data and Updated Development Strategy for Darlifarnib June 3, 2026 3:15 PM EDTCompany ParticipantsTroy ...
NEW YORK, April 17, 2026--(BUSINESS WIRE)--Volastra Therapeutics, a clinical-stage oncology company pioneering therapies targeting chromosomal instability (CIN), today announced multiple scientific ...
As the FDA formally recognizes real-world evidence as eligible confirmatory evidence for drug approval, sponsors face a growing imperative to build the data infrastructure, organizational alignment, ...
Brings more than 20 years of neurology, clinical development, and translational experience as AstronauTx prepares to advance its lead programmes into clinical developmentAstronauTx also appoints Deb ...
Oversubscribed Series B financing co-led by new investors Columbus Venture Partners and Mérieux Equity Partners, with ...
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS ® platform to develop in vivo gene editing therapies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results